Exploiting graft-versus-tumour responses using donor leukocyte infusions

Best Practice and Research: Clinical Haematology

Volumn 14, Issue 4, 2001, Pages 723-739

  Peggs, Karl S ^a   Mackinnon, Stephen ^a  

^a UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Adoptive immunotherapy; Allogeneic transplant; Donor leukocyte infusion; Graft versus host; Graft versus tumour

Indexed keywords

ALEMTUZUMAB; ANTIGEN; ANTINEOPLASTIC AGENT; CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; GAMMA INTERFERON; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 11; INTERLEUKIN 4; PERFORIN; THYMOCYTE ANTIBODY; TUMOR ANTIGEN;

ALLOGENIC BONE MARROW TRANSPLANTATION; ALLOGRAFT; ARTICLE; BONE MARROW TOXICITY; CANCER RECURRENCE; CANCER REGRESSION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DONOR; DRUG WITHDRAWAL; EFFECTOR CELL; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; ISOGRAFT; LEUKOCYTE TRANSFUSION; LYMPHOCYTE DEPLETION; PANCYTOPENIA; PRIORITY JOURNAL; RISK MANAGEMENT; T LYMPHOCYTE; TARGET CELL; ALLOTRANSPLANTATION; BLOOD DISEASE; IMMUNOLOGY; METHODOLOGY; REVIEW; STEM CELL TRANSPLANTATION; T LYMPHOCYTE SUBPOPULATION;

ANTIGENS, NEOPLASM; GRAFT VS LEUKEMIA EFFECT; HEMATOLOGIC NEOPLASMS; HUMANS; LEUKOCYTE TRANSFUSION; STEM CELL TRANSPLANTATION; T-LYMPHOCYTE SUBSETS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0035544311     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1053/beha.2001.0169     Document Type: Article

References (108)

1. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: A randomized trial of two irradiation regimens
2. Hematologic relapse of chronic myelogenous leukemia following allogeneic bone marrow transplantation: Apparent graft-versus-leukemia effect following abrupt discontinuation of immunosuppression
3. Durable complete remission of acute nonlymphocytic leukemia associated with discontinuation of immunosuppression following relapse after allogeneic bone marrow transplantation. A case report of a probable graft-versus-leukemia effect
4. Remission of relapsed leukaemia during a graft-versus-host reaction. A 'graft-versus-leukaemia reaction' in man?
5. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts
6. Antileukemic effect of chronic graft-versus-host disease: Contribution to improved survival after allogeneic marrow transplantation
7. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia
8. Identical-twin bone marrow transplants for leukemia
9. T-cell depletion of HLA-identical transplants in leukemia
10. Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-I reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse
11. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients
12. Donor leukocyte infusions for chronic myeloid leukemia in relapse after allogeneic bone marrow transplantation
13. Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation
14. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: Efficacy and toxicity of a defined T-cell dose
15. Adoptive immunotherapy for recurrent CML after BMT
16. Interferon-alpha and donor buffy coat transfusions for treatment of relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation
17. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia
18. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: The case for giving donor leukocyte transfusion before the onset of hematologic relapse
19. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: Separation of graft-versus-leukemia responses from graft-versus-host disease
20. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients
21. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation
22. Donor lymphocyte infusions (DLI) in patients with chronic myeloid leukemia following allogeneic bone marrow transplantation
23. Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogenic stem cell transplant: Where we now stand
24. Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: Equal efficacy of lymphocytes from sibling and matched unrelated donors
25. Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions
26. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia
27. Long-term follow-up of patients who achieved complete remission after donor leukocyte infusions
28. The rate and kinetics of molecular response to donor leucocyte transfusions in chronic myeloid leukaemia patients treated for relapse after allogeneic bone marrow transplantation
29. Donor leukocyte infusion for leukemic relapse after allogeneic marrow transplantation: Lack of residual donor hematopoiesis predicts aplasia
30. Adoptive immunotherapy in human and canine chimeras - The role of interferon alfa
31. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation
32. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes
33. T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: Freedom from relapse in the absence of graft-versus-host-disease
34. Donor leukocyte infusions in acute lymphocytic leukemia
35. Ex vivo generation of human anti-pre-B leukemia-specific autologous cytolytic T cells
36. Graft-versus-myeloma effect: Proof of principle
37. Graft-versus-myeloma effect in two cases
38. Graft-versus-myeloma effect
39. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation
40. Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow transplantation (BMT): Evidence for a graft-versus-myeloma effect
41. Donor leukocyte infusions for multiple myeloma
42. Graft-versus-myeloma after donor leukocyte infusion: Maintenance of marrow remission but extramedullary relapse with plasmacytomas
43. Adoptive T-cell therapy
44. High response rate in refractory and poor-risK multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions
45. Non-myeloablative allogeneic transplantation with adjuvant dose-escalated lymphocyte infusions for multiple myeloma
46. Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor
47. Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia
48. Management of lymphoma recurrence after allogeneic transplantation: The relevance of graft-versus-lymphoma effect
49. Allogenic bone marrow transplantation for low-grade lymphoma
50. Hematopoietic stem cell transplantation for chronic lymphocytic leukemia
51. Transplant-lite: Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies
52. Allogeneic hematopoietic transplantation for mantle-cell lymphoma: Molecular remissions and evidence of graft-versus-malignancy
53. T-cell memory: Lessons from Epstein-Barr virus infection in man
54. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation
55. Donor mononuclear cell infusions as therapy for B-cell lymphoproliferative disorder following allogeneic bone marrow transplant
56. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation
57. Effect of Epstein-Barr virus infection on response to chemotherapy and survival in Hodgkin's disease
58. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease
59. Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer
60. Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer
61. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogenic peripheral-blood stem-cell transplantation
62. + cytotoxic T-lymphocyte clones from a patient with severe graft-versus-host disease after allogeneic bone marrow transplantation: Implications for graft-versus-leukemia reactivity
63. Graft-versus-leukaemia following allogeneic bone marrow transplantation: Emergence of cytotoxic T lymphocytes reacting to host leukaemia cells
64. Distinct T cell populations distinguish chronic myeloid leukaemia cells from lymphocytes in the same individual: A model for separating GVHD from GVL reactions
65. Specific recognition of human leukemic cells by allogeneic T cells: II. Evidence for HLA-D restricted determinants on leukemic cells that are crossreactive with determinants present on unrelated nonleukemic cells
66. Allogeneic T-cell clones able to selectively destroy Philadelphia chromosome-bearing (Phl+) human leukemia lines can also Phl- cells from the same patient
67. Cellular and cytokine-mediated effects of CD4-positive lymphocyte lines generated in vitro against chronic myelogenous leukemia
68. + T lymphocytes can exert cytoxicity to chronic myeloid leukaemia cells processing and presenting exogenous antigen
69. Association of natural killer cell immune recovery with a graft-versus-leukemia effect independent of graft-versus-host disease following allogeneic bone marrow transplantation
70. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation
71. Graft-versus-leukaemia activity can be predicted by natural cytotoxicity against leukaemia cells
72. + T-cell subset inhibits antigen-specific T-cell responses and prevents colitis
73. Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy
74. Ifn-alpha and il-10 induce the differentiation of human type l t regulatory cells
75. Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-beta I-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients
76. Specific human cellular immunity to bcr-abl oncogene-derived peptides
77. Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia
78. Minimal residual disease is more common in patients who have mixed T-cell chimerism after bone marrow transplantation for chronic myelogenous leukemia
79. Conversion to full donor chimerism following donor lymphocyte infusion is associated with disease response in patients with multiple myeloma
80. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease
81. Graft-versus-host reaction spares normal stem cells in chronic myelogenous leukemia
82. Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WTI
83. Targeted T-cell therapy for human leukemia: Cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells
84. Immunotherapeutic strategies for the treatment of plasma cell malignancies
85. Growth inhibition of clonogenic leukemic precursor cells by minor histocompatibility antigen-specific cytotoxic T lymphocytes
86. Minor histocompatibility antigens as targets for T-cell therapy after bone marrow transplantation
87. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens
88. CD8(+) minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells
89. Retention of graft-versus-leukemia using selective depletion of CD8-positive T lymphocytes for prevention of graft-versus-host disease following bone marrow transplantation for chronic myelogenous leukemia
90. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation
91. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant
92. Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-v-host disease
93. A PRI-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia
94. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor
95. Specific depletion of alloreactive T cells in HLA-identical siblings: A method for separating graft-versus-host and graft-versus-leukaemia reactions
96. Effective depletion of alloreactive lymphocytes from peripheral blood mononuclear cell preparations
97. Efficient depletion of alloreactive donor T lymphocytes based on expression of two activation-induced antigens (CD25 and CD69)
98. Transplantation of anergic histoincompatible bone marrow allografts
99. Use of suicide gene-expressing donor T-cells to control alloreactivity after haematopoietic stem cell transplantation
100. Pharmacologic doses of granulocyte colony-stimulating factor affect cytokine production by lymphocytes in vitro and in vivo
101. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: A report from the Société Française de Greffe de Moelle
102. New strategies in allogeneic stem cell transplantation: Immunotherapy using irradiated allogeneic T cells
103. Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect
104. New strategies for bone marrow transplantation
105. Mini-allografts: Ongoing trials in humans
106. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotheraphy: Harnessing graft-versus-leukemia without myeloablative therapy
107. Graft-versus-tumor induction with donor leukocyte infusions as primary therapy for patients with malignancies
108. In vivo CAMPATH-I H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation